Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Gefitinib on Apatinib PK in NSCLC
NCT04390984Phase 1Unknown
- Sponsor
- Hengrui
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve over dosing interval. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04390984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390984.